

### Blueteq Forms In Development

02/07/2026

**Notice:** We are currently reviewing our list of providers. If you require any additional information, please contact us directly at [NWJCCBlueteq@wales.nhs.uk](mailto:NWJCCBlueteq@wales.nhs.uk).

Medicine Generic Name	Reference	Indication	Age Range	Initiation Form	Continuation Form	NWJCC Directorate	Policy
<b>Agalsidase alfa (M4C)</b>	<b>Policy</b>	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	7-17 years	In development	In development	Women & Children	M4C
<b>Agalsidase beta (M4C)</b>	<b>Policy</b>	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	8-17 years	In development	In development	Women & Children	M4C
<b>Ambrisentan</b>	<b>AWMSG 4819</b>	Treatment of pulmonary arterial hypertension (PAH)	8-99 years	In development	In development	In development	In development
<b>Bevacizumab</b>	<b>Policy</b>	Treatment of vestibular schwannoma in neurofibromatosis type 2	0-99 years	In development	In development	Neurosciences, Long Term Conditions & Rare Diseases	CP254
<b>Caplacizumab</b>	<b>TA667</b>	In combination with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura	12-99 years	In development	In development	Cancer and Blood	In development
<b>Certolizumab pegol (M4C)</b>	<b>TA445</b>	Treatment of active psoriatic arthritis after inadequate response to DMARDs	Post-pubescent	In development	In development	Women & Children	M4C
<b>Emicizumab</b>	<b>Policy</b>	Prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages)	0-99 years	In development	In development	Cancer and Blood	PPS167
<b>Emicizumab</b>	<b>Policy</b>	Prophylaxis in people with congenital haemophilia A without Factor VIII inhibitors (all ages)	0-99 years	In development	In development	Cancer and Blood	PPS189
<b>Galsulfase</b>	<b>AWMSG 0524</b>	Treatment of long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome)	5-99 years	In development	In development	Women & Children	In development
<b>Garadacimab</b>	<b>TA1101</b>	Prevention of recurrent attacks of hereditary angioedema in people 12 years and over	12-99 years	In development	In development	In development	In development
<b>Golimumab (M4C)</b>	<b>TA220</b>	Treatment of psoriatic arthritis	Post-pubescent	In development	In development	In development	M4C
<b>Holoclax</b>	<b>TA467</b>	Treatment of limbal stem cell deficiency after eye burns	In development	In development	In development	In development	In development
<b>Icatibant acetate</b>	<b>AWMSG 3293</b>	Treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency	2-99 years	In development	In development	Cancer and Blood	In development
<b>Infliximab (M4C)</b>	<b>TA329</b>	Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy	6-17 years	In development	In development	Women & Children	In development
<b>Iptacopan (M4C)</b>	<b>TA1000</b>	Treatment of paroxysmal nocturnal haemoglobinuria in adults	Post-pubescent	In development	In development	Cancer and Blood	M4C
<b>Lanadelumab</b>	<b>TA606</b>	Prevention of recurrent attacks of hereditary angioedema	12-99 years	In development	In development	Cancer and Blood	In development
<b>Lanadelumab (M4C)</b>	<b>TA606</b>	Prevention of recurrent attacks of hereditary angioedema	12-99 years	In development	In development	In development	M4C
<b>Larotrectinib</b>	<b>TA630</b>	Treatment NTRK fusion-positive solid tumours	0-17 years	In development	In development	Women & Children	In development
<b>Marstacimab</b>	<b>TA1073</b>	Severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over	12-99 years	In development	In development	In development	In development
<b>Mifamurtide</b>	<b>TA235</b>	Treatment of osteosarcoma	2-17 years	In development	In development	Women & Children	In development
<b>Nivolumab-relatlimab</b>	<b>TA950</b>	For untreated unresectable or metastatic melanoma	12-17 years	In development	In development	Women & Children	In development
<b>Obecabtagene autoleucel</b>	<b>TA1116</b>	Treatment of stage 2/refractory Philadelphia negative or positive B cell precursor acute lymphoblastic leukaemia in patients aged 26 years and older	26-99 years	In development	Not applicable	Cancer and Blood	In development
<b>Pembrolizumab</b>	<b>TA772</b>	Treatment of relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies	3-17 years	In development	In development	In development	In development
<b>Rituximab / Eculizumab</b>	<b>Policy</b>	Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in people with haemoglobinopathies	0-99 years	In development	In development	In development	In development
<b>Romiplostim (M4C)</b>	<b>TA211</b>	Treatment of chronic immune thrombocytopenia	1-17 years	In development	In development	In development	M4C
<b>Ruxolitinib</b>	<b>TA840</b>	Treatment of chronic graft versus host disease that responds inadequately to corticosteroids in people 12 years and over	12-17 years	In development	In development	In development	In development
<b>Ruxolitinib (M4C)</b>	<b>TA840</b>	Treatment of chronic graft versus host disease that responds inadequately to corticosteroids	2-11 years	In development	In development	In development	M4C
<b>Secukinumab (M4C)</b>	<b>TA445</b>	Treatment of active psoriatic arthritis after inadequate response to DMARDs	6-17 years	In development	In development	Women & Children	M4C
<b>Selexpig</b>	<b>AWMSG 700</b>	Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not	18-99 years	In development	In development	Cardiac	PP105
<b>Selpercatinib</b>	<b>TA1039</b>	Treatment of advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over	12-17 years	In development	Not applicable	Cancer and Blood	In development
<b>Talimogene laherparepvec</b>	<b>TA410</b>	Treatment of unresectable metastatic melanoma	0-99 years	In development	Not applicable	Cancer and Blood	In development
<b>Velmanase alfa</b>	<b>HST29</b>	Treatment of alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.	0-17 years	In development	In development	In development	CP55
<b>Vutrisiran</b>	<b>TA1115</b>	Treatment of transthyretin amyloidosis with cardiomyopathy.	18-99 years	In development	In development	Neurosciences, Long Term Conditions & Rare Diseases	In development